Free Trial Information
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...III trial of the tubulin inhibitor in April, with data coming in 4Q21.TARGETSCSNK1E (CKIε) – Casein kinase 1...
Read More
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

...in upfront, development and milestones payments, plus tiered royalties. TARGETSPI3Kδ – Phosphoinositide 3-kinase deltaCSNK1E (CKI-epsilon) – Casein kinase 1...
Read More
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

...into Cerevel” ). Biogen Inc. (NASDAQ:BIIB) will acquire PF-05251749, a CNS-penetrant small molecule inhibitor of CSNK1...
...a Phase Ia trial in 2018 of the compound, which showed an acceptable safety profile. CSNK1...
...from the University of South Florida showed in a September paper in Scientific Reports that CSNK1...
Read More
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Renal cancer In vitro and cell culture studies identified an aminothiazole-based negative allosteric modulator (NAM) of CSNK2 that could help treat renal cell carcinoma (RCC). Chemical synthesis and in vitro testing of aminothiazole analogs...
Read More
BioCentury | Apr 13, 2018
Clinical News

ProMIS identifies new beta amyloid epitope to treat AD

Researchers at the University of British Columbia reported preclinical data showing that PMN300 decreased soluble beta amyloid aggregates and neurotoxicity in the brain in two mouse models of Alzheimer's disease. In a paper published in...
Read More
BioCentury | Jan 12, 2018
Company News

Exelixis, StemSynergy in CSNK1A activator deal

...StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha...
...Inc. (NASDAQ:EXEL), South San Francisco, Calif. Business: Cancer Elizabeth S. Eaton Exelixis Inc. StemSynergy Therapeutics Inc. Casein kinase 1 alpha (CSNK1A) (CKI-alpha...
Read More
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
Read More
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active...
Read More
BioCentury | Jul 18, 2017
Distillery Therapeutics

Cancer

...testing the compound in additional models of Wnt signaling-driven colorectal cancer. TARGET/MARKER/PATHWAY: Casein kinase 1 α (CSNK1A; CKI-α...
...David J. Robbins, University of Miami, Miami, Fla. email: drobbins@med.miami.edu Hongjiang Li University of Miami Casein kinase 1 alpha (CSNK1A) (CKI-alpha...
Read More
BioCentury | Feb 28, 2017
Distillery Therapeutics

Neurology

INDICATION: Huntington's disease (HD) Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue samples...
Read More
Items per page:
1 - 10 of 39